Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new recipe for cancer care: social prescriptions and Bite-Sized learning

NCT ID NCT07788729

Symptom relief Sponsor: University of Regensburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This pilot trial tests a new approach to support cancer patients and their caregivers. The intervention combines social prescriptions—connecting people to community resources—with short online learning modules and regular symptom check-ins. The goal is to see if this package can improve quality of life and help patients feel more in control of their care, particularly for those in underserved rural areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A multicomponent intervention combining social prescriptions, web-based micro-learning modules, and stepwise care based on symptom monitoring.
What this could lead to
If successful, this approach could offer a low-cost, scalable way to improve quality of life and care for cancer patients, especially those in rural areas.
What could go wrong
This is a pilot study, so results are preliminary and may not generalize. The intervention's complexity could also make it hard to implement consistently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 384 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients: * aged at least 18 years * primary diagnosis of early-stage or advanced-stage lung cancer, colorectal cancer, hematological neoplasm or malignant melanoma within the past 12 months * expected survival of at least 18 months * sufficient German language proficiency to complete questionnaires and interviews * attendance at the medical oncology units of participating hospitals * provision of written informed consent * ECOG Performance Status 0-2 * ability to name an eligible SP. Inclusion criteria for Support Persons: * being nominated by the patient as someone who provides support, encouragement or assistance in coping with their cancer * aged at least 18 years * proficiency in German * provision of written informed consent. Exclusion Criteria: Inability to * provide informed consent * independently complete interviews and/or questionnaires due to impaired speech, vigilance, or comprehension.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer colorectal neoplasm hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lung cancer lung neoplasm melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Colorectal cancer Hematological cancer Lung cancer Malignant melanoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité - University Medicine Berlin

    NOT_YET_RECRUITING

    Berlin, Germany

  • Faculty of Law, Business & Economics, Inst. for Healthcare Management & Health Sciences

    ACTIVE_NOT_RECRUITING

    Bayreuth, Germany

  • University Hospital Augsburg

    NOT_YET_RECRUITING

    Augsburg, Bavaria, Germany

  • University Hospital Erlangen

    NOT_YET_RECRUITING

    Erlangen, Bavaria, Germany

  • University Hospital Köln

    NOT_YET_RECRUITING

    Cologne, Germany

  • University Hospital Regensburg

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • University Hospital Würzburg

    NOT_YET_RECRUITING

    Würzburg, Bavaria, Germany

  • University Regensburg

    ACTIVE_NOT_RECRUITING

    Regensburg, Bavaria, 93053, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.